Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2022-05-16 Regulatory Filings
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement (an Asset Purchase Agreement), a press release about the agreement, and a planned conference call with a slide presentation. There are no financial statements or detailed financial results presented, only disclosures about the transaction and related events. This type of filing is a regulatory announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-05-16 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text explicitly states it is a 'Definitive Additional Materials' filing related to a proxy statement. Proxy statements and related materials are classified under 'Proxy Solicitation & Information Statement' (PSI). The document length is short and it is not a full annual report or other financial report. Therefore, the correct classification is PSI with high confidence.
2022-05-12 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2022-05-12 English
FORM 10-Q
Interim / Quarterly Report Q1 2022
2022-05-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 12, 2022. It announces the issuance of a press release and a presentation regarding the company's financial results for the first quarter ended March 31, 2022. The document itself does not contain the financial results or detailed financial statements but rather furnishes the press release and presentation as exhibits. The text explicitly states that the press release and presentation are "furnished" and not "filed" for purposes of the Exchange Act, indicating this document is an announcement of the release of financial results and related materials, not the financial report itself. The document length is under 5,000 characters and primarily serves to notify the market of the release of financial results and a conference call. Therefore, according to the "Menu vs Meal" rule, this is a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR).
2022-05-12 English
FORM 10-K
Annual Report FY 2021
2022-03-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.